(WNY News Now) – If you bought certain generic prescription drugs between 2010 and 2016, you may be eligible for a refund as part of a $49.1 million settlement with two major pharmaceutical companies.
HARRISBURG – Attorney General Michelle Henry joined a coalition of 50 states and territories in announcing cooperation agreements and settlements with Heritage Pharmaceuticals and Apotex — totaling $49.1 million — regarding the companies’ price inflation and manipulation and other efforts to reduce options for consumers.
According to the settlements, the generic prescription drug companies will pay a combined $49.1 million to consumers who purchased their products between 2010 and 2016. The companies will also cooperate in ongoing multistate litigation, led by Connecticut, against 30 corporate defendants and 25 individual executives. The settlements come as the states prepare for the first trial in those matters to be held in Hartford, Conn.
If you purchased a generic prescription drug from either Heritage or Apotex between 2010 and 2016, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182, email [email protected] or visit www.AGGenericDrugs.com.
“Generic versions of prescription drugs are supposed to be more affordable, while offering the same health benefits to those who need them,” Attorney General Henry said. “These greedy companies harmed Pennsylvanians by intentionally inflating prices and reducing competition.”
Pharmacists in Pennsylvania are authorized to swap out name-brand prescriptions for generic brands, unless prescribed specifically the name-brand prescription.
Connecticut’s Assistant Attorney General Joseph Nielsen is the lead attorney for a coalition of nearly all states and territories filing three antitrust complaints, starting first in 2016. The first Complaint included Heritage and 17 other corporate Defendants, two individual Defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have since entered into settlement agreements and are cooperating. The second Complaint was filed in 2019 against Teva Pharmaceuticals and 19 of the nation’s largest generic drug manufacturers.